September 30, 2022
VIA EDGAR
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, DC 20549-3720
Attention: Dillon Hagius
| Re: | Ventyx Biosciences, Inc. (the “Registrant”) |
Registration Statement on Form S-1 (File No. 333-267626)
Request for Acceleration
Acceleration Request
Requested Date: October 4, 2022
Requested Time: 4:00 PM ET
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Ventyx Biosciences, Inc. (the “Company”) hereby requests that the above-referenced Registration Statement on Form S-1 (File No. 333-267626) (the “Registration Statement”) be declared effective at the “Requested Date” and “Requested Time” set forth above or at such later time as the Company or its counsel may orally request via telephone call to the staff (the “Staff”) of the Division of Corporation Finance of the Securities and Exchange Commission (the “Commission”). Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Wilson Sonsini Goodrich & Rosati, P.C., by calling Martin Waters at (858) 350-2308.
The Company understands that the Staff will consider this request as confirmation by the Company of its awareness of its responsibilities under the federal securities laws as they relate to the offering of the securities covered by the Registration Statements.
[Signature page follows]
Securities and Exchange Commission
September 30, 2022
Page 2
| Sincerely, |
| VENTYX BIOSCIENCES, INC. |
| /s/ Raju Mohan |
| Raju Mohan |
| Chief Executive Officer |
Enclosures
| cc: | Christopher Krueger, Ventyx Biosciences, Inc. |
Martin Auster, Ventyx Biosciences, Inc.
Martin J. Waters, Wilson Sonsini Goodrich & Rosati, P.C.
Robert L Wernli, Jr., Wilson Sonsini Goodrich & Rosati, P.C.